Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints

Roivant Sciences Ltd. (NASDAQ: ROIV) is considered one of the best stocks to buy under $20.

On September 17, Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study. This was a 52-week, placebo-controlled trial evaluating the once-daily oral drug brepocitinib in patients with dermatomyositis (DM).

The trial enrolled 241 subjects globally and is noted as a significant step forward in the treatment of this condition.
https://ca.finance.yahoo.com/news/roivant-brepocitinib-phase-3-dermatomyositis-205446652.html